Bedside to Biotech: Building Trust, Storytelling in Science, and Pediatric Cancer Innovation
In this episode of Clinical Trialblazers, host Alberto Grignolo sits down with Dr. Sam Blackman, co-founder and former Chief Medical Officer of Day One Biopharmaceuticals, board member of the Pediatric Brain Tumor Foundation, Bonum Therapeutics and CureSearch for Children's Cancer, and the new Entrepreneur in Residence at Google Ventures. Sam talks about his career journey from physician to biotech executive, and navigating the complexities of clinical trials, especially within pediatric oncology. He also discusses the critical need to connect the science, patients, and investment thesis together into a coherent story when fundraising in drug development.
- 2:37 - How he was pulled to pediatric medicine
- 6:00 - His decision to transition into drug development to impact exponentially more patients.
- 16:40 - The importance of connecting you vision to your company name
- 26:04 - How making those risky decisions in drug development can have profound impacts on patient outcomes
- 40:00 - The Power of Storytelling in Science and Business
- 47:57 - Advice for biotech entrepreneurs seeking capital
Related Insights
CTB Webinar
Extend your funding runway: How to maintain capital efficiency in an improving market
Mar 10, 2026
CTB Podcast
Pioneering oncology trials with AVEO Oncology
Mar 11, 2025
CTB Podcast
Introducing Clinical Trialblazers!
Mar 6, 2025
CTB Blog
Decoding FDA's new ‘plausible mechanism framework’ guidance: what drug developers need to know
Feb 27, 2026
CTB Report
Faster paths to proof of concept
Feb 19, 2026
CTB Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
CTB Video
JCA strategy: Predicting and prioritizing PICOs
Jan 22, 2026
CTB Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
CTB Podcast
Leadership Lessons from Biotech Innovators
Nov 18, 2025
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
CTB Podcast
Breaking Barriers in Gene Therapy: Miquel Vila-Perello's Vision for Curing Untreatable Diseases
Sep 15, 2025
CTB Podcast
Investing in Innovation: Lyla Bibi’s Perspective on Biotech Markets
Aug 11, 2025
Related Insights
CTB Webinar
Extend your funding runway: How to maintain capital efficiency in an improving market
Mar 10, 2026
CTB Podcast
Pioneering oncology trials with AVEO Oncology
Mar 11, 2025
CTB Podcast
Introducing Clinical Trialblazers!
Mar 6, 2025
CTB Blog
Decoding FDA's new ‘plausible mechanism framework’ guidance: what drug developers need to know
Feb 27, 2026
CTB Report
Faster paths to proof of concept
Feb 19, 2026
CTB Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
CTB Video
JCA strategy: Predicting and prioritizing PICOs
Jan 22, 2026
CTB Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
CTB Podcast
Leadership Lessons from Biotech Innovators
Nov 18, 2025
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
CTB Podcast
Breaking Barriers in Gene Therapy: Miquel Vila-Perello's Vision for Curing Untreatable Diseases
Sep 15, 2025
CTB Podcast
Investing in Innovation: Lyla Bibi’s Perspective on Biotech Markets
Aug 11, 2025